Lianne Gensler, MD

Associate Professor

Education
2019 - Diversity, Equity, and Inclusion Champion Training, University of California
Certificate, 2008 - Medicine (Advance Training in Clinical Research), University of California, San Francisco
M.D., 2001 - School of Medicine, University of California Irvine
B.S., 1995 - Microbiology & Molecular Genetics, University of California, Los Angeles
Residency, - School of Medicine, University of California, San Francisco
Honors and Awards
  • Ira M. Goldstein Teaching award in Rheumatology, University of California, San Francisco, 2015
  • Research Mentoring Award, University of California, San Francisco, 2015
  • Spondylitis Association Young Investigator Award, 2012
Websites
Publications
  1. Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial.
  2. Patient-reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID-19 Pandemic.
  3. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 pivotal studies.
  4. The changing profile of ankylosing spondylitis in the biologic era.
  5. Cardiovascular risk scores in axial spondyloarthritis versus the general population: A cross-sectional study.
  6. Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.
  7. Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey.
  8. Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci.
  9. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
  10. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
  11. Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis.
  12. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
  13. EP38 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies.
  14. P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA.
  15. P284 Certolizumab pegol-treated patients with non-radiographic axSpA demonstrate improvements in sleep quality and other patient reported outcomes.
  16. Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort.
  17. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review.
  18. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
  19. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis.
  20. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
  21. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
  22. A Terminal Event. Reply.
  23. A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values.
  24. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
  25. Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap.
  26. Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?
  27. Nonsteroidal Anti-inflammatory Drug use is Associated with Incident Hypertension in Ankylosing Spondylitis.
  28. A Terminal Event.
  29. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
  30. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
  31. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.
  32. MR distribution of active inflammatory and chronic structural sacroiliac joint changes in axial spondyloarthropathy: Challenging conventional wisdom.
  33. Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
  34. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
  35. A 52-Week Randomized Placebo-Controlled Trial of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis.
  36. E098 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542).
  37. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis.
  38. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
  39. Nonradiographic axial spondyloarthritis.
  40. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
  41. HLA class I and II alleles in susceptibility to ankylosing spondylitis.
  42. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.
  43. THU0242 Pregnancy outcomes and disease activity in women with axial spondyloarthritis: a systematic literature review.
  44. A multiple imputation method based on weighted quantile regression models for longitudinal censored biomarker data with missing values at early visits.
  45. Successful treatment of mucous membrane pemphigoid with bortezomib.
  46. Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort.
  47. Clinical Images: Ochronotic arthropathy.
  48. Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups.
  49. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
  50. Validity and Responsiveness of a 10-Item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population.
  51. Cervical Spinal Fracture and Other Diagnoses Associated With Mortality in Hospitalized Ankylosing Spondylitis Patients.
  52. FRI0398 Pharmacologic Therapy and Radiographic Progression in Ankylosing Spondylitis: A Growing Controversy.
  53. FRI0434 Prevalence of Structural Cardiac Disease and Diastolic Dysfunction in Axial Spondyloarthritis: A Prospective Case-Control Study.
  54. SAT0380 Nsaids Modify The Effect of Tumor Necrosis Factor Inhibitors on New Bone Formation in Ankylosing Spondylitis.
  55. SAT0400 Clinical Factors Impacting Statin Usage in A Longitudinal Ankylosing Spondylitis Cohort.
  56. Physical activity in axial spondyloarthritis-tails from bench to bedside.
  57. ECHOCARDIOGRAPHIC EVALUATION OF CARDIOVASCULAR DISEASE IN ANKYLOSING SPONDYLITIS: A PROSPECTIVE CASE-CONTROL STUDY.
  58. National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia.
  59. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
  60. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
  61. Updates in adult-onset Still disease: Atypical cutaneous manifestations and associations with delayed malignancy.
  62. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.
  63. Axial spondyloarthritis: the heart of the matter.
  64. ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients.
  65. Reply: To PMID 25154344.
  66. Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis.
  67. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
  68. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns.
  69. New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey.
  70. Spine fractures in ankylosing spondylitis: a case report and review of imaging as well as predisposing factors to falls and fractures.
  71. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis.
  72. Development and validation of the spondyloarthritis radiography module for calibration of readers using the modified Stoke Ankylosing Spondylitis Spine Score.
  73. The impact of tumor necrosis factor a inhibitors on radiographic progression in ankylosing spondylitis.
  74. FRI0468 Socioeconomic status predicts radiographic progression in ankylosing spondylitis.
  75. MICA, a gene contributing strong susceptibility to ankylosing spondylitis.
  76. SAT0273 Lower socioeconomic status and smoking are associated with greater radiographic disease severity in axial spondyloarthritis.
  77. Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?
  78. Glucocorticoids: complications to anticipate and prevent.
  79. Neutrophilic urticaria with systemic inflammation: a case series.
  80. Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.
  81. Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease.
  82. Is there a higher genetic load of susceptibility loci in familial ankylosing spondylitis?
  83. The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis.
  84. 112 Clinical features of ankylosing spondylitis.
  85. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort.
  86. Recognition and treatment of juvenile-onset spondyloarthritis.
  87. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.
  88. Clinical problem-solving. One surprise after another.
  89. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation.
  90. Does use of intravascular ultrasound accelerate arteriopathy in heart transplant recipients?